目的 觀察研究靈寶護心丹治療原發(fā)性微血管性心絞痛的臨床療效及安全性。方法 選取2019年12月—2022年6月就診于南陽市中心醫(yī)院的原發(fā)性微血管性心絞痛患者76例，按隨機數(shù)字表法分為對照組（38例）和治療組（38例）。對照組患者給予冠狀動脈粥樣硬化性心臟病二級預防常規(guī)治療，治療組在上述治療基礎上口服靈寶護心丹，4粒/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者西雅圖心絞痛調(diào)查量表（SQA）評分、運動平板結(jié)果和冠脈血流儲備（CFR）。結(jié)果 治療后，治療組總有效率為92.11%，明顯高于對照組（71.05%，P＜0.05）。治療后，兩組SAQ評分在各方面均高于治療前（P＜0.05），且治療組顯著高于對照組（P＜0.05）。治療后，兩組患者運動平板總運動時間明顯升高，而ST段最大壓低程度明顯下降（P＜0.05），且治療組患者運動平板結(jié)果改善均顯著優(yōu)于對照組（P＜0.05）。治療后，兩組CFR指標比治療前明顯升高（P＜0.05），且治療組患者冠脈血流儲備情況顯著高于對照組（P＜0.05）。結(jié)論 靈寶護心丹能夠改善微血管心絞痛患者的臨床癥狀，提高冠脈血流儲備，增強運動耐量并改善患者生活質(zhì)量。

Objective To observe and study the clinical efficacy and safety of Lingbao Huxindan in the treatment of primary microvascular angina pectoris. Methods Patients (76 cases) with primary microvascular angina pectoris in Nanyang Central Hospital from December 2019 to June 2022 were divided into control (38 cases) and treatment (38 cases) group according to random number table method. Patients in the control group were administered with routine treatment for secondary prevention of coronary atherosclerotic heart disease. Patients in the treatment group were po administered with Lingbao Huxindan on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, the SAQ scores, exercise treadmill results, and CFR in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 92.11%, which was significantly higher than that of the control group (71.05%, P < 0.05). After treatment, the SAQ score of the two groups was higher than that before treatment (P < 0.05), and which of the treatment group was significantly higher than that of the control group (P < 0.05). After treatment, the total exercise time of treadmill was significantly increased, while the maximum depression of ST was significantly decreased in both groups (P < 0.05), and the improvement of treadmill results in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the CFR index in two groups was significantly higher than that before treatment (P < 0.05), and the coronary flow reserve in the treatment group was significantly higher than that in the control group (P < 0.05). Conclusion Lingbao Huxindan can improve the clinical symptoms of patients with microvascular angina pectoris, increase coronary blood flow reserve, enhance exercise tolerance and improve the quality of life of patients.

R972

國家重點研發(fā)計劃項目（2018YFC1312400）